AGILENT TECHNOLOGIES INC

Agilent’s new EU CE‑mark for PD‑L1 IHC 22C3 (SK006) boosts its precision‑oncology portfolio, driving revenue growth and competitive edge while navigating reimbursement and regulatory hurdles.

Agilent backs HALO X‑ray Technologies to fast‑track a high‑resolution diffraction scanner, boosting airport security and cutting operational costs while opening doors to safer, faster medical imaging.

Agilent’s $600 M debt deal and Biocare acquisition boost its laboratory‑diagnostics portfolio, fueling innovation, global reach, and higher margins in a value‑based healthcare market.

Agilent’s pre‑market jump hides more than momentum—life science growth, diagnostic demand, AI opportunities, and ESG‑driven risk mitigation shape its future.

Agilent Technologies posts 10% revenue growth, 33% operating income jump, and strategic Biocare acquisition—fueling 8‑10% CAGR and AI‑driven diagnostics expansion.

Agilent Technologies reports a 10% revenue rise and expanded margins in Q2 FY 2026, driven by strong Life Sciences, Diagnostics and Ignite platform growth.

Agilent names Michael Buckner as new chief legal officer, boosting governance and IP protection as the company tackles evolving regulatory challenges and future M&A.

Agilent Technologies’ latest report shows how high‑margin RF modules fuel growth and offer a blueprint for pharma and biotech firms tackling market access, patent cliffs, and M&A in fast‑moving sectors.

Discover how Agilent’s portfolio shifts reveal key pharma‑biotech trends, from reimbursement strategies and patent cliffs to M&A dynamics, guiding smarter commercial decisions.

March 18 2026 S&P 500 drops 1.5%—a careful look at sector swings, high dividend yields, and tightening rates shows why investors stay defensive yet seek tech‑driven upside.